HRs for OS according to the presence of each genetic alteration in ATL
| Variable . | Univariate . | Adjusted . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Whole group (n = 226) | ||||||
| Age ≥70 y | 1.84 | 1.27-2.68 | .001 | |||
| Subtype: aggressive | 4.12 | 2.66-6.38 | <.001 | |||
| PRKCB mutations | 1.46 | 1.01-2.12 | .046 | 1.59 | 1.08-2.34 | .019 |
| STAT3 mutations | 0.60 | 0.38-0.95 | .028 | 1.05 | 0.64-1.72 | .837 |
| IRF4 mutations | 2.20 | 1.37-3.54 | .001 | 1.86 | 1.13-3.05 | .015 |
| Amp (9p24): PD-L1 | 2.33 | 1.47-3.71 | <.001 | 2.24 | 1.41-3.58 | .001 |
| Del (6p22): ATXN1 | 1.91 | 1.19-3.08 | .008 | 1.16 | 0.71-1.90 | .564 |
| Del (6q21): PRDM1 | 1.71 | 1.05-2.81 | .033 | 1.36 | 0.82-2.24 | .230 |
| Del (9p21): CDKN2A | 1.78 | 1.21-2.62 | .004 | 1.22 | 0.81-1.82 | .342 |
| Del (13q32): GPR183 | 2.06 | 1.36-3.13 | .001 | 1.14 | 0.73-1.79 | .562 |
| Aggressive subtype (n = 152) | ||||||
| Age ≥70 y | 1.77 | 1.16-2.70 | .009 | |||
| JCOG-PI high-risk | 3.61 | 2.30-5.67 | <.001 | |||
| Treatment | ||||||
| VCAP-AMP-VECP | 0.63 | 0.40-1.00 | .051 | |||
| Other | 1.04 | 0.52-2.05 | .917 | |||
| PRKCB mutations | 1.50 | 0.98-2.28 | .060 | 1.84 | 1.16-2.93 | .010 |
| Amp (9p24): PD-L1 | 1.72 | 1.01-2.94 | .047 | 1.75 | 1.02-3.01 | .042 |
| Del (10p11): CCDC7 | 0.59 | 0.36-0.96 | .034 | 0.74 | 0.44-1.24 | .253 |
| Indolent subtype (n = 74) | ||||||
| Age ≥70 y | 1.57 | 0.69-3.57 | .285 | |||
| Subtype: unfavorable chronic | 3.74 | 1.51-9.26 | .004 | |||
| PLCG1 mutations | 2.26 | 1.07-4.80 | .033 | 1.98 | 0.93-4.22 | .077 |
| VAV1 mutations | 2.44 | 0.96-6.24 | .062 | 1.69 | 0.65-4.38 | .282 |
| IRF4 mutations | 4.23 | 0.93-19.15 | .061 | 4.97 | 1.09-22.67 | .038 |
| Amp (9p24): PD-L1 | 5.09 | 1.93-13.42 | .001 | 4.47 | 1.68-11.87 | .003 |
| Del (7q34): TRB | 2.55 | 1.17-5.59 | .019 | 2.12 | 0.95-4.74 | .067 |
| Del (9p21): CDKN2A | 6.35 | 2.45-16.50 | <.001 | 4.26 | 1.60-11.36 | .004 |
| Variable . | Univariate . | Adjusted . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Whole group (n = 226) | ||||||
| Age ≥70 y | 1.84 | 1.27-2.68 | .001 | |||
| Subtype: aggressive | 4.12 | 2.66-6.38 | <.001 | |||
| PRKCB mutations | 1.46 | 1.01-2.12 | .046 | 1.59 | 1.08-2.34 | .019 |
| STAT3 mutations | 0.60 | 0.38-0.95 | .028 | 1.05 | 0.64-1.72 | .837 |
| IRF4 mutations | 2.20 | 1.37-3.54 | .001 | 1.86 | 1.13-3.05 | .015 |
| Amp (9p24): PD-L1 | 2.33 | 1.47-3.71 | <.001 | 2.24 | 1.41-3.58 | .001 |
| Del (6p22): ATXN1 | 1.91 | 1.19-3.08 | .008 | 1.16 | 0.71-1.90 | .564 |
| Del (6q21): PRDM1 | 1.71 | 1.05-2.81 | .033 | 1.36 | 0.82-2.24 | .230 |
| Del (9p21): CDKN2A | 1.78 | 1.21-2.62 | .004 | 1.22 | 0.81-1.82 | .342 |
| Del (13q32): GPR183 | 2.06 | 1.36-3.13 | .001 | 1.14 | 0.73-1.79 | .562 |
| Aggressive subtype (n = 152) | ||||||
| Age ≥70 y | 1.77 | 1.16-2.70 | .009 | |||
| JCOG-PI high-risk | 3.61 | 2.30-5.67 | <.001 | |||
| Treatment | ||||||
| VCAP-AMP-VECP | 0.63 | 0.40-1.00 | .051 | |||
| Other | 1.04 | 0.52-2.05 | .917 | |||
| PRKCB mutations | 1.50 | 0.98-2.28 | .060 | 1.84 | 1.16-2.93 | .010 |
| Amp (9p24): PD-L1 | 1.72 | 1.01-2.94 | .047 | 1.75 | 1.02-3.01 | .042 |
| Del (10p11): CCDC7 | 0.59 | 0.36-0.96 | .034 | 0.74 | 0.44-1.24 | .253 |
| Indolent subtype (n = 74) | ||||||
| Age ≥70 y | 1.57 | 0.69-3.57 | .285 | |||
| Subtype: unfavorable chronic | 3.74 | 1.51-9.26 | .004 | |||
| PLCG1 mutations | 2.26 | 1.07-4.80 | .033 | 1.98 | 0.93-4.22 | .077 |
| VAV1 mutations | 2.44 | 0.96-6.24 | .062 | 1.69 | 0.65-4.38 | .282 |
| IRF4 mutations | 4.23 | 0.93-19.15 | .061 | 4.97 | 1.09-22.67 | .038 |
| Amp (9p24): PD-L1 | 5.09 | 1.93-13.42 | .001 | 4.47 | 1.68-11.87 | .003 |
| Del (7q34): TRB | 2.55 | 1.17-5.59 | .019 | 2.12 | 0.95-4.74 | .067 |
| Del (9p21): CDKN2A | 6.35 | 2.45-16.50 | <.001 | 4.26 | 1.60-11.36 | .004 |
Top, HRs for OS associated with age (<70 years vs ≥70 years), subtype (aggressive vs indolent), and genetic alterations in 226 ATL patients by univariate analyses. Values adjusted for disease subtype and age are also shown. Middle, HRs for OS associated with age, JCOG-PI category (high-risk vs moderate-risk), treatment content (VCAP-AMP-VECP or others vs CHOP/CHOP-like), and genetic alterations in 152 aggressive ATL patients by univariate analyses. Values adjusted for age, JCOG-PI, and treatment content are also shown. Bottom, HRs for OS associated with age, subtype (unfavorable chronic vs favorable chronic and smoldering), and genetic alterations in 74 indolent ATL patients by univariate analyses. Values adjusted for age and subtype are also shown. Recurrently mutated genes (n = 13), as well as focal amplifications (n = 4) and deletions (n = 16) present in >10% of ATL cases were examined, and only significant alterations in univariate analyses are shown. The prognostic impact on OS was evaluated by univariate and multivariate Cox regression analyses.
Amp, amplification; AMP, doxorubicin, ranimustine, and prednisone; CI, confidence interval; Del, deletion; VCAP, vincristine, cyclophosphamide, doxorubicin, and prednisone; VECP, vindesine, etoposide, carboplatin, and prednisone.